Kg. Parhofer et al., Low density lipoprotein apolipoprotein B metabolism: comparison of two methods to establish kinetic parameters, ATHEROSCLER, 144(1), 1999, pp. 159-166
Citations number
28
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Elevated plasma cholesterol concentrations represent a major risk factor fo
r coronary artery disease (CAD). Low density lipoprotein (LDL)-apolipoprote
in (apo) B plays a key role in this process. Metabolic parameters of LDL-ap
oB such as fractional catabolic rate (FCR) and production rate help to unde
rstand the underlying pathomechanisms of elevated LDL-apoB and are usually
determined with tracer studies (gold-standard). However, these parameters c
an also be calculated from the rebound of plasma LDL-apoB concentration fol
lowing a perturbation such as apheresis, if it is assumed that the perturba
tion itself does not affect metabolic parameters. LDL-apoB metabolism was d
etermined using two methods in eight hyperlipoproteinemic patients (47 +/-
15 years, body mass index (BMI) 27.5 +/- 4.1 kg/m): (a) by endogenous label
ing using D-3-leucine (bolus 5 mg/kg) as tracer and multicompartmental mode
ling; and (b) by fitting a monoexponential equation to LDL-apoB rebound con
centration data following apheresis. LDL-apoB metabolic parameters determin
ed using the two methods (mean +/- S.D.; FCR-tracer: 0.18 +/- 0.07 per day,
FCR-rebound: 0.27 +/- 0.25 per day; production-tracer: 12.0 +/- 3.9 mg/kg
per day; production-rebound: 15.2 +/- 8.0 mg/kg per day) were not correlate
d, were not concordant (intraclass correlation coefficient), and were not s
ignificantly different. Furthermore, only in five of the eight patients the
rebound analysis predicted LDL-apoB steady-state concentrations that were
within 20% of observed steady-state concentrations. These results indicate
that parameters derived from LDL-apoB mass rebound following apheresis cann
ot be used as a surrogate for parameters established with tracer methodolog
y probably because the assumption that apheresis does not affect metabolic
parameters of LDL-apoB may not be true in all patients. (C) 1999 Elsevier S
cience Ireland Ltd. All rights reserved.